EMT-like Activation in CLL Provides Novel Therapeutic Target

2022

Full text Open access: Green Metadata (CSL-JSON)
DOI 10.1182/blood-2022-162696
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction: There is growing interest in the role of Epithelial to Mesenchymal Transition (EMT) regulators in immune cells development, but the functional role of EMT in B-cell biology and transformation remains obscured.1, 2 The outcomes of the "classical" EMT activation of epithelial cells are known; committed migratory cells do not divide and become resistant to apoptotic stimuli.Importantly, EMT supports migratory cells' "stem cell-like" properties, allowing differentiation into more than one cell type and/or terminal differentiation and senescence.Chronic lymphocytic leukaemia (CLL) cells engage with antigen and microenvironment stimuli in tissue sites that lead to proliferation, followed by their egress from the tissue sites into the peripheral blood.This lifecycle implies functional changes altering CLL cell movement.3 Here we show EMT-like activation in CLL that correlates with disease progression and transformation.We identified a targetable candidate and show it can be inhibited by small molecule ligands.